Clinical outcomes of HIV-1 infected patients switched from complex multi-tablet regimens to tenofovir alafenamide based single-tablet regimens plus a boosted protease inhibitor in...

por Rolle, Charlotte-Paige, Nguyen, Vu, Hinestrosa, Federico, DeJesus, Edwin
Publicado 2020

Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients liv...

por Rolle, Charlotte-Paige, Nguyen, Vu, Hinestrosa, Federico, DeJesus, Edwin
Publicado 2021

1603. Efficacy, safety and tolerability of switching to dolutegravir/lamivudine in virologically suppressed adults living with HIV on bictegravir/emtricitabine/tenofovir alafenamid...

por Rolle, Charlotte-Paige M, Castano, Jamie, Nguyen, Vu, Hinestrosa, Federico, DeJesus, Edwin
Publicado 2023

2482. Clinical Outcomes of Once-Daily Darunavir in Treatment-Experienced Patients with Darunavir Resistance Associated Mutations Through 48 Weeks of Treatment

por Rolle, Charlotte-Paige M, Marquez, Omar, Nguyen, Vu, Hinestrosa, Federico, DeJesus, Edwin
Publicado 2019

Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV

por Rolle, Charlotte-Paige, Nguyen, Vu, Patel, Kiran, Cruz, Dan, DeJesus, Edwin, Hinestrosa, Federico
Publicado 2021

661. Ibalizumab Efficacy and Safety Through 48 Weeks of Treatment: Results of an Expanded Access Protocol (TMB-311)

por Emu, Brinda, DeJesus, Edwin, Berhe, Mezgebe, Leider, Jason, Creticos, Catherine, Weinheimer, Steve, Cohen, Zvi
Publicado 2019

1012. Efficacy, safety and tolerability of switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-1 infected virologically-suppressed older adults in a real-...

por Rolle, Charlotte-Paige M, Nguyen, Vu, Patel, Kiran, Cruz, Dan, Hinestrosa, Federico, DeJesus, Edwin
Publicado 2020

889. Early Discontinuations and Adverse Events Among Treatment-Naïve Patients Initiating Integrase Inhibitors in a Real-world Setting

por Rolle, Charlotte-Paige M, Castano, Jamie, Nguyen, Vu, Patel, Kiran, Hinestrosa, Federico, DeJesus, Edwin
Publicado 2021

Efficacy and Safety of Abacavir/Lamivudine/Zidovudine Plus Tenofovir in HBV/HIV-1 Coinfected Adults: 48-Week Data

por Rodriguez, Allan E, DeJesus, Edwin, Williams, Vanessa, Irlbeck, David, Ross, Lisa, Ha, Belinda, Lancaster, Charles T
Publicado 2010

Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults

por DeJesus, Edwin, Saleh, Soundos, Cheng, Sue, van der Mey, Dorina, Becker, Corina, Frey, Reiner, Unger, Sigrun, Mueck, Wolfgang
Publicado 2019

2486. Clinical Outcomes of Patients Treated with Dolutegravir Functional Monotherapy or Dolutegravir plus an Active Non-cytosine Nucleoside Analog: A Retrospective Observational Co...

por Rolle, Charlotte-Paige M, Bryant, Beth, Tucker, Colton J, Camila Castro, Maria, Nguyen, Vu, Hinestrosa, Federico, DeJesus, Edwin
Publicado 2019

1027. Long-Term Efficacy, Safety, and Durability of Ibalizumab-Based Regimens in Subgroup of TMB-202 Participants

por Towner, William, DeJesus, Edwin, Schrader, Shannon, De Vente, Jerome, McGary, Colleen, Zogheib, Mohammed, Weinheimer, Steven, Mesquita, Pedro
Publicado 2020

A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice...

por Kumar, Princy N, Salvato, Patricia, LaMarca, Anthony, DeJesus, Edwin, Patel, Parul, McClernon, Daniel, Florance, Allison, Shaefer, Mark S
Publicado 2009

Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice

por Lackey, Philip, Mills, Anthony, Carpio, Felix, Hsu, Ricky, DeJesus, Edwin, Pierone, Gerald, Henegar, Cassidy, Fusco, Jennifer, Fusco, Gregory, Wohlfeiler, Mike
Publicado 2016

A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus

por Thompson, Melanie, Saag, Michael, DeJesus, Edwin, Gathe, Joseph, Lalezari, Jay, Landay, Alan L., Cade, Jerry, Enejosa, Jeffrey, Lefebvre, Eric, Feinberg, Judith
Publicado 2016

Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults

por Gallant, Joel E., Thompson, Melanie, DeJesus, Edwin, Voskuhl, Gene W., Wei, Xuelian, Zhang, Heather, White, Kirsten, Cheng, Andrew, Quirk, Erin, Martin, Hal
Publicado 2017

Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide

por Sax, Paul E., DeJesus, Edwin, Crofoot, Gordon, Ward, Douglas, Benson, Paul, Dretler, Robin, Mills, Anthony, Brinson, Cynthia, Wei, Xuelian, Collins, Sean E., Cheng, Andrew
Publicado 2018

Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT

por Smith, Kimberly Y, Weinberg, Winkler G, DeJesus, Edwin, Fischl, Margaret A, Liao, Qiming, Ross, Lisa L, Pakes, Gary E, Pappa, Keith A, Lancaster, C Tracey
Publicado 2008

Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infec...

por Kumar, Princy, DeJesus, Edwin, Huhn, Gregory, Sloan, Louis, Small, Catherine Butkus, Edelstein, Howard, Felizarta, Franco, Hao, Ritche, Ross, Lisa, Stancil, Britt, Pappa, Keith, Ha, Belinda
Publicado 2013

Simplification to Abacavir/Lamivudine + Atazanavir Maintains Viral Suppression and Improves Bone and Renal Biomarkers in ASSURE, a Randomized, Open Label, Non-Inferiority Trial

por Wohl, David A., Bhatti, Laveeza, Small, Catherine B., Edelstein, Howard, Zhao, Henry H., Margolis, David A., DeJesus, Edwin, Weinberg, Winkler G., Ross, Lisa L., Shaefer, Mark S.
Publicado 2014